Reclast (Zoledronic Acid) Compounding Legal Status, FDA Approval, and Safety
A guide to zoledronic acid's FDA approval history, current compounding legal status, label requirements, and post-market safety data. Updated with primary-source citations.
Zoledronic Acid: Regulatory History
7 source-based articles maintained by the HealthRX.com Editorial Team.
7articles
3topic areas covered
Jan 20, 2025latest review
Zoledronic Acid: Regulatory History library
Showing 7 of 7 clinical reviews.
Reclast (Zoledronic Acid) EMA vs FDA Approach: Labels, Safety, and Regulatory Differences
A comparison of how the FDA and EMA regulate zoledronic acid (Reclast/Aclasta), covering approved indications, label differences, post-market safety requirements, and what each approach means for patients.
Reclast (Zoledronic Acid) FAERS Safety Signals: Post-Market Surveillance Data and FDA Label Updates
A clinical review of zoledronic acid (Reclast) safety signals reported to the FDA Adverse Event Reporting System (FAERS), including osteonecrosis of the jaw, atypical femoral fractures, renal toxicity, and atrial fibrillation.
Reclast (Zoledronic Acid) FDA Approval History
Complete FDA approval timeline for zoledronic acid (Reclast/Zometa), including original indications, label expansions, safety communications, and post-market surveillance findings.
Reclast (Zoledronic Acid) Global Regulatory Status: FDA Approval, EMA Authorization, and Post-Market Safety
Complete regulatory overview of zoledronic acid (Reclast/Aclasta) covering FDA approval history, EMA authorization, labeled indications, boxed warnings, and global post-market surveillance data.
Reclast (Zoledronic Acid) Label Updates 2020 to 2026: FDA Safety Changes Explained
A review of what is publicly documented about Reclast (zoledronic acid) FDA labeling and safety themes since 2020, including renal monitoring, atypical femoral fracture, osteonecrosis of the jaw, and hypocalcemia language, with guidance on verifying the current Prescribing Information before use.
Reclast (Zoledronic Acid): Pipeline, Next-Gen Bisphosphonates, and What Comes After
A clinical overview of zoledronic acid's regulatory history, current label, post-market safety data, and the next-generation bone agents in development that may eventually succeed it.